Introduction: Communication in Medicine {#S1}
=======================================

For centuries, physicians have depended on the use of written information to gain knowledge and the first known examples were written on clay or papyrus. Book printing and binding -- introduced by Gutenberg in the 15th century -- revolutionized and accelerated the distribution of information. The first medical journals were launched already in the eighteenth century ([@B1]--[@B4]) and by the middle of the nineteenth century "*if you were a scientist you were expected to read French, English, and German*" ([@B5]). At the time, the German language was considered the primary language of international scientific communication because German scientists held the leading position in many disciplines, including chemistry, mathematics, and physics ([@B6]). In the nineteenth century and early twentieth century, German was also the language of scientific publication in Vienna, then the reputed center of medicine, psychology, and psychiatry, as well as in Czechoslovakia, Poland, Scandinavia, and the Netherlands ([@B6]). Even in English-speaking countries such as the UK and the United States, scientists were expected to read German to keep up with the developments in their fields ([@B6], [@B7]). After the Nazi regime came into power in 1933, German successively lost its predominance as a scientific language, scientists -- who had left Germany and took exile in the United States or the UK -- started publishing their work in English ([@B6], [@B8]). However, not until 1960 English fully took over as the primary language of science ([@B9]). In fact, many German medical journals with a long-publishing tradition successively changed to publish in English to increase the global visibility of their articles published ([@B9]). Today, more than 98% of all scientific articles published are published in English ([@B8]).

Communicating Progress in Medicine {#S2}
==================================

Communication of scientific discoveries and medical progress is directly linked to population health. In that context, translational medicine is concerned with the translation of research discoveries into clinical application for the prevention, diagnosis, and treatment of human diseases. On February 12, 1974, when at the University of Zürich German physician Andreas Grüntzig, M.D. (1939--1985, Figure [1](#F1){ref-type="fig"}), for the first time applied a balloon-tipped dilating catheter to treat a patient with peripheral vascular disease ([@B10], [@B11]), he could not know that 40 years later his method would be considered as one of the most important therapeutic advances and outstanding examples of translational medicine of the twentieth century ([@B12]). Though was a major breakthrough for vascular medicine, and Grüntzig and his colleague, chemist Heinrich Hopff (with whom he had developed the new polyvinyl chloride (PVC) balloon device ([@B10])), wanted to publish both the balloon catheter concept and the first patient cases treated with this new method. This was at a time when the first Xerox machines had arrived in offices just a few years before, when there were no computers, calculators, or an internet; at a time when statistical analysis had to be done without the help of statistics computer programs, when scientific manuscripts and their carbon copies had be written on a typewriter, and when figures had to be hand-drawn with rulers and black ink.

![**Andreas Grüntzig, M.D. (1939--1985), photograph taken 1982 in Nürnberg, Germany**. Photograph courtesy of Felix Mahler, M.D., and used with his permission.](fcvm-01-00006-g001){#F1}

For the publication of their findings Grüntzig and Hopff chose a journal that only published articles in German ([@B10]). Automatically, this meant that access to this new medical information was going to be neither rapid nor global. In fact, access to the new information was delayed by the printing process which in those days could require several months up to 2 years. The latter happened to one of the research groups who independently discovered the vascular activity of an endothelium-derived peptide ([@B13]), which was later identified as endothelin ([@B14]). Moreover, the publication by Grüntzig and Hopff could be read only by those individuals proficient in the German language, and was restricted to German-speaking countries in which printed journal copies were distributed among its subscribers. Fortunately, the article did contain an English abstract (Figure [2](#F2){ref-type="fig"}). In October of 1977, Grüntzig went global with his intellectual property by filing a patent application for the balloon angioplasty device in Switzerland, Germany, France, the United Kingdom, the United States, and Japan ([@B15]). However, this patent was not issued until 1980, 6 years after Grüntzig had begun treating patients using his new method. Regardless of the patent being issued, it took a full 5 years until Grüntzig's new balloon angioplasty method finally reached the United States ([@B16]). The restriction of dissemination of Grüntzig's new treatment of peripheral vascular disease within the medical community can serve as a good example of how access to important new medical information can be delayed namely by limiting the communication required for the attention an information may deserve. Ironically, the journal originally chosen by Grüntzig and Hopff in 1974 to publish his first balloon angioplasty cases even today still publishes most of its articles in German; however, it may occasionally consider manuscripts written in English.

![**First page of the original article published in 1974 in German by Andreas Grüntzig, M.D. and Heinrich Hopff, Ph.D., reporting Grüntzig's the new method of balloon angioplasty and results of the first 15 patients with peripheral artery disease successfully treated with this new therapy**. Note the insert of an English abstract on the right of the page. Reproduced from Grüntzig and Hopff ([@B10]), with permission of the publisher.](fcvm-01-00006-g002){#F2}

Open Access to Knowledge in Vascular Medicine {#S3}
=============================================

Advancing medical knowledge and progress is not only linked to the scientific quality of a discovery, which will determine its acceptance by the peers, but also by its communication and sharing of new findings with the medical community. All these factors determine whether new knowledge will be able to advance and improve clinical practice, medical education, and ultimately, patient care and human health. Medical publishing has recently witnessed a revolution through open access publishing and the online availability of published information, which can be accessed and printed instantaneously from any computer connected to the internet. The advantages of such a development have been realized more than a decade ago ([@B17]) and are obvious: articles published "open access" allow physicians to retrieve the most current information instantaneously without delay, utilize said information for clinical decision making, teaching of medical students and fellows. Finally, physicians and medical scientists can use open access journals to communicate their own research or to share clinical knowledge with their colleagues.

Printed medical journals and text books by nature have a limited number of printed pages. This limitation, which is simply due to economic reasons and costs, often prevents important and noteworthy articles to be published in widely read journals. In fact, due to the printed pages limit many journals in medicine or science can accept only 20% or less of all manuscripts submitted. As a result, many otherwise fine articles are published with considerable delay or sometimes cannot even be published at all in a particular journal. Unfortunately, this also slows down advancement of medical progress and understanding of new scientific questions being addressed in a manuscript. Some scientists in the field have even abandoned submitting manuscripts to some of the key journals, as they feel that the way by which these journals handle manuscript submissions distorts the scientific process ([@B18], [@B19]).

A New Era for Vascular Medicine {#S4}
===============================

The key element of quality control in medical and scientific publishing always has been and will remain high-level, independent peer-review of studies by experts knowledgeable in a particular field, regardless whether a manuscript contains data or content related to medicine or science. In most of today's medical journals, authors do not learn about the identity of those who review or reviewed a particular manuscript. Sometimes, they can be direct competitors, working in the same area, which may go unnoticed by the Editors. In addition, reviewers normally report their manuscript assessments to the editors who will then make a decision about the fate of the manuscript which will then be communicated to the corresponding author. While there is no need to criticize this approach, it often does lead to a considerable delay until a final decision can be reached, particularly, when several revisions of a manuscript are required. What is and will remain important, though is the independence and the high scientific expertise of any editor or reviewer assessing a manuscript submitted for review.

As with all Frontiers journals, we are taking the same new approach with *Vascular Medicine* to increase transparency of the review and decision processes and to shorten the review process while maintaining a high quality of the scientific peer-review. Implementing the Frontiers interactive review, authors are required to directly interact with reviewers and the Editor after the manuscript has been submitted. This approach not only dramatically shortens the time required to address issues raised by the reviewers but also allows authors to directly communicate with their reviewers who at that stage remain anonymous. Only after the paper has been accepted for publication authors will learn the identity of their reviewers, and names and affiliations will be listed on the published manuscript.

A New Journal: Goals and Expectations {#S5}
=====================================

We anticipate and hope that *Vascular Medicine* will develop into an open access knowledge platform with a strong clinical focus allowing physicians, health professionals, and vascular disease specialists to obtain and communicate information relevant to teaching and practicing vascular medicine. Readers and authors will have access to information on atherosclerotic vascular disease affecting the aorta and peripheral, renovisceral, and extracranial arteries, as well as related clinical complications such as acute and chronic critical limb ischemia and arterial aneurysms. Moreover, the journal offers articles on medical and interventional treatment of vascular diseases, particularly, studies on endovascular surgery and vascular interventions ([@B20]). In addition to atherosclerotic vascular disease, one of the main areas in vascular medicine, the Journal also covers other kinds of vascular diseases involving the macro- or microcirculation, vascular malformations, venous disease, and lymphatic diseases ([@B21]). The Journal will also feature articles on primary and secondary vascular disease prevention ([@B22]--[@B24]), new therapies ([@B25]--[@B27]), translational medicine ([@B28]), and medical education in the field of vascular medicine.

Although *Vascular Medicine* is primarily focusing on clinical medicine, human trials, and translational clinical research ([@B12], [@B29]), manuscripts reporting results from preclinical and experimental studies will be considered as long they are related to vascular disease and advance the understanding of the pathophysiology of the related disease condition or help to develop new treatments ([@B28]). Articles made available in *Vascular Medicine* are meant to continuously increase insights in the understanding of disease and treatment and to foster medical education -- all to advance clinical practice and patient care in vascular medicine.

Forty years ago the vascular medicine pioneer Andreas Grüntzig, M.D., at our institution published the first results of balloon angioplasty treatment of patients with peripheral vascular disease (Figure [3](#F3){ref-type="fig"}) in a journal that was only available in German-speaking countries and to readers proficient in the German language ([@B10]). Times have changed. As the Editors of *Vascular Medicine*, we are confident that open access provided to its content published in today's global language of science ([@B8]) will advance communication and distribution of new and most up-to-date information on clinical practice and medical knowledge in vascular medicine ([@B17], [@B30]). We anticipate that the ongoing transformation of scientific publishing through open access -- which *Frontiers in Cardiovascular Medicine* has become part of -- will further accelerate this process to make new information available even faster. Immediate, unrestricted, and free global access to the most current published knowledge will play a role in maintaining and advancing human vascular health.

![**Supplemental information ("Zur Arbeit Grüntzig, Hopff") to the article depicted in Figure [2](#F2){ref-type="fig"}, showing arterial angiograms of two patients with peripheral artery disease before (left), during (middle), and after (right) percutaneous balloon angioplasty performed by Andreas Grüntzig, M.D**. The first angiogram in panel 1 (Abb. 1) indicates left superficial femoral artery stenosis in a 71-year-old man, the procedure was performed on April 9, 1974. The left angiogram panel 2 (Abb. 2) indicates a high-grade stenosis of the left common iliac artery in a 73-year-old male patient, the procedure was performed on March 6, 1974. Note the differently sized angioplasty balloons, both in diameter and length. The German figure legend indicates that both patients were free of symptoms on follow-up 3 months after the procedure. Reproduced from Grüntzig and Hopff ([@B10]), with permission of the publisher.](fcvm-01-00006-g003){#F3}
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